This book explores active surveillance in prostate cancer, covering patient selection, risk assessment, 'cancer hysteria' in patients, identifying triggers for intervention, use of PSA kinetics and MRI information and the roles of surveillance and focal therapy.

This fully updated and revised new edition provides a comprehensive, state-of-the art review of this field, and will serve as a valuable resource for clinicians, surgeons and researchers with an interest in prostate cancer. The book reviews new data about molecular characteristics of the disease, profiles the new grading system for prostate cancer introduced in 2015, and provides new perspectives about imaging of prostate cancer, as well as the role of targeted biopsies. The text summarizes the role of biomarkers and MRI in patient selection and management and details the world wide results of active surveillance. Specific chapters address communication and ethical issues, QOL outcomes, economic aspects, and psycho-social aspects of surveillance. The role of focal therapy for low risk disease is summarized, and the data supporting preventive interventions during surveillance reviewed. This text will serve as a very useful resource for physicians and researchers dealing with,and interested in this common malignancy, as it provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.

Profiles the new grading system for prostate cancer introduced in 2015 Fully updated and revised new edition Authored by recognized experts in their respective fields Includes supplementary material: sn.pub/extras

Autorentext

Laurence Klotz, MD, FRCSC, CM

Professor of Surgery, University of Toronto

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Inhalt

Cancer Overdiagnosis and Overtreatment.- Can We Screen and Still Reduce Overdiagnosis?.- The Role of Fear in Overdiagnosis and Overtreatment.- Ethical and Legal Considerations in Active Surveillance for Prostate Cancer.- Gleason 6 Tumors Should Still Be Labeled As Cancer.- Risk Based Selection for Active Surveillance.- Surveillance at the Margins: Management of High Volume Gleason 6, PSA > 10, or Gleason 3+4.- How Should Patients on Active Surveillance be Followed?.- Triggers for Intervention.- MR Imaging in Prostate Tumor Volume Assessment: How Accurate?.- Can MRI Replace Biopsy in Men on Surveillance?.- Tissue Based Markers for Risk Prediction.- International AS Registry: The Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance Initiative.- Better Informed Decision Making to Optimize Patient Selection.- How Does QOL Compare Between Surveillance and Active Treatment?.- The Potential Benefits of Diet and Physical Activity among Active Surveillance Patients with Low-Burden Prostate Cancer.- Is there a Role for Pharmacologic Manipulation to Prevent Progression in Men on Active Surveillance? The Role of 5-ARIs, Statins, and Metformin.- The Update of Active Surveillance around the World: Utilization and Outcomes.- Tissue Preservation Active Surveillance and Focal Therapy as Complimentary Strategies.- The Economics of Active Surveillance for Prostate Cancer.- Research Questions in Active Surveillance.